Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 11/20 | 1.00 |
| ▸ | GABRG2 | P18507 | 11/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 11/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 11/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 11/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 11/20 | 1.00 |
| ▸ | GABRA6 | Q16445 | 8/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 7/20 | 1.00 |
| ▸ | GABRP | O00591 | 6/20 | 1.00 |
| ▸ | GABRD | O14764 | 6/20 | 1.00 |
| ▸ | GABRB1 | P18505 | 6/20 | 1.00 |
| ▸ | GABRB2 | P47870 | 6/20 | 1.00 |
| ▸ | GABRE | P78334 | 6/20 | 1.00 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 1.00 |
| ▸ | GABRG3 | Q99928 | 6/20 | 1.00 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29766941 | 0.93 | ALDH1A1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2214572 | 0.93 | ALDH1A1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7384200 | 0.92 | ALDH1A1 (0.93) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL601711 | 0.90 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL29672619 | 0.90 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL30274389 | 0.90 | GABRA1 (1.00) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL8146977 | 0.88 | GABRA1 (0.78) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7380516 | 0.87 | GABRA1 (0.77) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Beta-Ccm SCHEMBL15648382 | 0.85 | GABRA1 (0.91) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL31163651 | 0.85 | GABRA1 (0.77) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260846-A1 | Novel methods for the treatment of cancer | Lankenau Institute for Medical Research (US) | 2010-12-15 | — | — | EP | claimed |
| EP-1606285-A4 | NOVEL IDO INHIBITORS AND METHODS OF USE | LANKENAU INST MEDICAL RES (US) | 2009-03-18 | — | — | EP | claimed |
| EP-1613308-A4 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INST MEDICAL RES (US) | 2008-02-20 | — | — | EP | claimed |
| US-20070173524-A1 | \"Novel ido inhibitors and methods of use | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-07-26 | — | — | US | claimed |
| US-20070099844-A1 | Novel methods for the treatment of cancer | LANKENAU INSTITUTE FOR MEDICAL RESEARCH | 2007-05-03 | — | — | US | claimed |
| EP-1613308-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | Lankenau Institute for Medical Research (US) | 2006-01-11 | — | — | EP | claimed |
| EP-1606285-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE | Lankenau Institute for Medical Research (US) | 2005-12-21 | — | — | EP | claimed |
| WO-2004094409-A1 | NOVEL IDO INHIBITORS AND METHODS OF USE | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| WO-2004093871-A1 | NOVEL METHODS FOR THE TREATMENT OF CANCER | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2004-11-04 | — | — | WO | claimed |
| EP-2260846-B1 | Novel methods for the treatment of cancer | LANKENAU INST MEDICAL RES (US) | 2018-11-28 | — | — | EP | disclosed |
| US-8569481-B2 | Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions | PHARMACEUTICALS, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8476454-B2 | IDO inhibitors and methods of use | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-07-02 | — | — | US | disclosed |
| US-8383613-B2 | Methods for the treatment of cancer | LANKENAU INSTITUTE FOR MEDICAL RESEARCH (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-5843396-A | Method for stabilizing radiolabeled organic compounds by adding a separate stabilizing compound | NEN LIFE SCIENCE PRODUCTS, INC. (US) | 1998-12-01 | — | — | US | disclosed |
| EP-0835233-A1 | COMPOSITION AND METHOD FOR STABILIZING RADIOLABELED ORGANIC COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5738836-A | Composition for stabilizing radiolabeled organic compounds | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1998-04-14 | — | — | US | disclosed |
| WO-1997001520-A1 | COMPOSITION AND METHOD FOR STABILIZING RADIOLABELED ORGANIC COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-01-16 | — | — | WO | disclosed |
| EP-0148660-A1 | Beta-carboline derivatives, process for their preparation and medicaments containing them | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1985-07-17 | — | — | EP | disclosed |
| US-4411881-A | Composition and method for stabilizing radiolabeled compounds using thiocarbonylated diethylenetriamines | NEW ENGLAND NUCLEAR CORPORATION (US) | 1983-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173524-A1 | \"Novel ido inhibitors and methods of use | IDO1, IDO2, INMT | GABRA1 3846/4885GABRG2 3501/4885GABRB3 2794/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | GABRA1 46/4885GABRG2 97/4885GABRB3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.